Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), announced the appointment of Steve Arkinstall, D.Phil., as its Chief Scientific Advisor. With over 30 years of global experience in biopharmaceutical research and development, Dr. Arkinstall brings a wealth of knowledge and proven leadership to Nona Biosciences. Dr. Arkinstall has demonstrated remarkable competence throughout his career.

He is a respected leader in drug discovery with substantial roles under his belt, including Research Head, Chief Scientific Officer (CSO), and Chief Executive Officer (CEO) positions at various pharmaceutical or biotech companies. Dr. Arkinstall served as CEO of Elstar Therapeutics and Revitope Oncology, companies advancing novel classes of multi-specific antibody-based cancer drugs. He previously was also the CSO of Kymab, an antibody therapeutics company founded in Cambridge, UK, prior to which he spent 16 years in progressively senior research leadership roles at EMD (Merck) Serono, and its associated entities across Europe and the United States.

Dr. Arkinstall's appointment is effective immediately, and he will play an integral role in guiding Nona's strategic direction, external alliances, and overall scientific operations.